The award recognizes CooperVision for its support of educational opportunities for students, including the sponsorship of a new eye care clinic.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, lectured on retinal updates at CRU 2025. The pair also covered the power of a low vision referral for patients with retinal disease.

The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.

Following a discussion on low-dose atropine, Paul Karpecki, OD, FAAO, shares his views on what the future of myopia management looks like.

Topline data from both phase 3 trials are expected in the second quarter of 2026, with NDA submission to follow thereafter.

Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.

Educational tools, visual aids can help children with visual impairments thrive.

Catch up on the top stories in optometry during the week of April 7-April 11.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

CLI Visionaries provide professional perspectives on best practices and highlight the EASY (Eyes, Awareness, Safety & You) Way program in the series.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

The Vision Council report highlights providers’ expectations and the perceived impact of economic factors including tariffs, inflation, staffing and hiring, and technological integration including telehealth and artificial intelligence.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, detailed the prevalence of the conditions, diagnostic tools, and treatment options.

Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

Dr Rachelle Lin highlights the urgent need for early intervention in childhood myopia, discusses associated retinal and systemic risks, and emphasizes the long-term impact of axial length control in reducing serious ocular complications.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Rachelle Lin, OD, MS, FAAO, and Quan Đông Nguyễn, MD, MSc, presented available treatment options and what is coming down the pipeline for retinal conditions.

The expansion will allow the company to double the number of intraocular lenses manufactured every year to 4 million.